Biotechnology
Our team regularly advises clients developing biotech products in areas including biotechnology derived proteins (such as insulin), immunologicals (such as vaccines and allergens), blood or plasma derived products, and engineered tissues.
Our team benefits from having several members of the group who have completed degrees in subjects including molecular biology, biochemistry and genetics. This knowledge enables us to quickly grasp technical concepts and provide nuanced and tailored advice.
We closely follow new developments and emerging trends in the biotech market. For example, we have been following the emerging regulatory pathways for biosimilars and advising clients on appropriate strategies.
We have worked with many well-known companies on their biological products, including Pfizer, Novartis, Regeneron, Amgen and Roche.
Explore our sectors
Meet our lawyers
News & insights
Publications: 20 January 2022
Kickoff of the UPC: UPC Protocol on Provisional Application now in force
On 19 January 2022, the Unified Patent Court (UPC) came to life as an international organisation. Now, the preparatory phase for the official start of the UPC system can begin.
News: 12 January 2022
Technology deals dominate the 2021 global M&A market
Allen & Overy’s latest M&A Insights report* shows that that the value of global M&A transactions surged to a record high of nearly USD5.8 trillion in 2021, an increase of 64% on 2020, and 48% higher…
Publications: 12 January 2022
The UK National Security and Investment Act 2021: the impact on M&A
The mergers and acquisitions (M&A) landscape in the UK changed on 4 January 2022 when the National Security and Investment Act 2021 (the Act) came fully into force. The following article has been…
Publications: 15 December 2020
Healthcare accent is on smaller deals
Transactions in the U.S. healthcare space rebounded in autumn, although with a greater proportion of smaller deals than in recent years.
Download our sector brochure
